Quest PharmaTech Inc.
Description Quest PharmaTech Inc. engages in the discovery, development, and commercialization of oncology product candidates in Asia. It develops a series of products for the treatment of cancer and dermatological conditions based on its SonoLight technology platform. The companys principal products include oregovomab, an immunotherapeutic product that is in Phase IIb clinical trial for the treatment of ovarian cancer; and SL017, a topical formulation for dermatology applications. It also develops SL052, an injectable formulation that is in Phase I clinical trials for the treatment of prostate cancer; and Anti MUC1 AR20.5, which has completed preclinical trials for the treatment of pancreatic cancer. The company has strategic collaboration with Alberta Research Council to develop a fermentation-based method to manufacture Hypocrellin B. Quest PharmaTech Inc. is headquartered in Edmonton, Canada. To view the detailed information, you need to SUBSCRIBE with us. |
 |